Medical device manufacturers entering multiple markets simultaneously must navigate four fundamentally different regulatory systems. The EU MDR and IVDR operate under a risk-based classification scheme with mandatory Notified Body involvement for most non-lowest-risk devices. The US FDA uses a three-tier system centred on substantial equivalence for the majority of devices. The UK has maintained a broadly EU-aligned framework but with distinct local representative requirements and an evolving relationship with CE marking. China's NMPA system requires national-level registration for all imported devices regardless of class, with a mandatory single China agent whose name appears on the registration certificate itself.
The table below compares these four systems across seven key dimensions. The narrative sections that follow analyse the most material differences in practice.
Quick Reference: EU MDR vs UK MDR vs US FDA vs China NMPA
| Dimension |
EU EU MDR 2017/745 / IVDR 2017/746 |
UK UK MDR 2002 (SI 2002/618) |
US FDA 21 CFR Part 820 / QMSR |
China NMPA Order 739 |
|---|---|---|---|---|
| Risk classification | 4 classes (I, IIa, IIb, III) for devices; 4 classes (A, B, C, D) for IVDs. 22 classification rules under Annex VIII of MDR. Class I mostly self-certified; Class IIa and above require Notified Body. | Same 4-class system as EU MDR (adopted from MDD framework). CE marking under EU MDR/IVDR accepted until 30 Jun 2030 for GB market access without separate UK conformity assessment. | 3 classes (I, II, III). Class I ~47% of device types (mostly exempt from premarket review). Class II ~43% (510(k) clearance). Class III ~10% (PMA approval required). | 3 classes (I, II, III). All imported devices subject to national NMPA registration regardless of class — unlike EU, even Class I imports require NMPA approval at the national level. |
| Market access route | CE marking with EU Declaration of Conformity. Non-EU manufacturers must appoint an EU Authorised Representative (Article 13 MDR). EUDAMED SRN must appear on device label from 28 May 2026. | CE marking (MDR/IVDR) accepted until 30 Jun 2030. Legacy MDD/AIMDD CE accepted until 30 Jun 2028. UK Responsible Person (UKRP) mandatory for all non-GB manufacturers. | 510(k) clearance (substantial equivalence to predicate), PMA approval (Class III), or De Novo classification (novel low/moderate risk). 21 CFR Part 807 establishment registration and device listing required for all. | NMPA registration certificate — issued nationally for all classes. Single China agent mandatory; agent name appears on the certificate and all labelling. CMDE technical evaluation conducted for all import registrations. |
| Quality system requirement | EU MDR Annex IX — based on ISO 13485:2016. Notified Body audits of QMS mandatory for Class IIa and above. Post-market surveillance and PSUR requirements active. | UK MDR 2002 QMS requirements broadly equivalent to EU MDR. PMS amendment regulations in force June 2025 strengthened PSUR and PMCF obligations for GB market. | FDA QMSR (revised 21 CFR Part 820, effective 2 Feb 2026) incorporates ISO 13485:2016 by reference. FDA inspection regime actively assesses QMSR conformance. | ISO 13485 (implemented as YY/T 0287) required for all registered devices. NMPA and provincial authorities conduct GMP inspections of manufacturing sites. Quality system documentation must be filed as part of the registration dossier. |
| Local representative obligation | EU Authorised Representative (EU AR) mandatory for all non-EU manufacturers under Article 11 MDR. EU AR registered in EUDAMED; SRN on device label. Single EU AR per manufacturer per device category. | UK Responsible Person (UKRP) mandatory for all non-GB manufacturers. Must be a legal entity established in Great Britain (not EU). Name and address on or with the device. Northern Ireland follows EU rules (no UKRP required). | US Agent mandatory for all foreign establishments under 21 CFR Part 807. US Agent registered with FDA; acts as point of contact for FDA communications. Does not appear on device labelling. | Single China agent mandatory under Order 739. Agent name appears on NMPA registration certificate and all device labelling. Changing the China agent requires certificate amendment — a significant operational constraint. |
| Premarket pathway | Conformity assessment with Notified Body for Class IIa and above. Technical documentation, clinical evaluation, and post-market surveillance plan required. Class I (non-sterile, non-measuring) self-certified with EU AR. | Same conformity assessment approach as EU MDR while CE recognition is in place. MHRA UKCA route via UK Approved Bodies available but not widely used. Consultation on future post-2030 route open as of early 2026. | 510(k) Premarket Notification for Class II (demonstrates substantial equivalence to a legally marketed predicate). PMA for Class III (clinical data required). De Novo for novel devices. FDA clears ~3,000 devices/year via 510(k). | NMPA registration via CMDE technical evaluation for all classes. Registration certificates valid 5 years. Class I registration is simpler but still nationally required for imports. No concept of substantial equivalence — each device is evaluated independently. |
| UDI requirement | UDI mandatory as part of EUDAMED device registration. UDI-DI and UDI-PI required on device labelling by class. EUDAMED UDI module mandatory from 28 May 2026. | UK UDI system currently aligned with EU approach for devices accepted under CE recognition. MHRA monitoring UDI implementation as part of wider framework review. | FDA UDI mandatory for all device classes — Class III from 2014, Class II from 2016, Class I (labelled) from 2020. UDI must appear on device label and in the Global UDI Database (GUDID). | China UDI phased in from 2021. Class III mandatory since 2021. Class II and Class I implementation on rolling schedule per NMPA. Separate national UDI Data Repository from EU/US systems. |
| Key 2026–2029 change | EUDAMED mandatory 28 May 2026. MDR transition cut-offs: Class III & IIb implantable Dec 2027; remaining classes Dec 2028. IVDR cut-offs: Class D Dec 2027, Class C Dec 2028, Class B/A sterile Dec 2029. | CE MDR/IVDR recognition window runs to 30 Jun 2030. MHRA consultation on indefinite CE recognition open Feb 2026 — outcome will determine post-2030 route. PMS amendments already in force (June 2025). | QMSR (revised 21 CFR Part 820) effective 2 Feb 2026 — all FDA-registered establishments must operate under QMSR now. Ongoing FDA review of digital health software and AI/ML device guidance. | NMPA certificate renewals at 5-year intervals ongoing. UDI phase-in for lower classes continues. Manufacturers should initiate renewal at least 12 months before certificate expiry. |
Classification Philosophy: MDR Risk Classes vs FDA's Three-Tier System
The EU MDR's four-class system for devices and four-class system for IVDs (applied separately under the IVDR) creates a more granular risk stratification than the FDA's three-tier approach. In practice, the most significant divergence is at the lower end of the risk spectrum. A Class I measuring or sterile device under the EU MDR requires Notified Body involvement — there is no equivalent FDA pathway that would require a 510(k) or PMA for a comparable device category. Conversely, a US Class II 510(k)-cleared device may face a Class IIa or IIb classification in the EU, triggering a Notified Body conformity assessment that was not required for the US approval. Manufacturers cannot assume that classification in one system maps directly to classification in another; a classification mapping exercise is a necessary first step for any multi-market strategy.
China's three-class system has a further distinguishing feature: the requirement for national NMPA registration at all class levels for imported devices. This is the most significant structural difference between China and the other three markets. A Class I device that is self-certified under the EU MDR, exempt from premarket review in the US, and accepted under CE marking in the UK will still require a full NMPA national registration before it can be placed on the Chinese market. This adds time and cost to the China market entry process that has no equivalent in the other three systems.
Quality System Requirements: ISO 13485 as the Common Thread
The most significant area of convergence across all four markets is the adoption of ISO 13485:2016 as the foundational quality management system standard. The EU MDR Annex IX references ISO 13485 as the basis for QMS conformity assessment by Notified Bodies. The FDA QMSR, effective 2 February 2026, incorporates ISO 13485:2016 directly into revised 21 CFR Part 820. China's NMPA requires ISO 13485 (implemented nationally as YY/T 0287) as part of the registration dossier. The UK PMS amendments in force from June 2025 aligned UK requirements more closely with the EU MDR PMS framework, which is itself ISO 13485-based.
The practical implication is that a well-implemented ISO 13485:2016 QMS provides a credible foundation for compliance in all four markets — but it is not sufficient on its own. The QMSR adds FDA-specific requirements on complaint files and CAPA documentation that go beyond the ISO 13485 text. The EU MDR Annex IX adds requirements for clinical evaluation and post-market surveillance that are not present in the FDA QMSR. China requires QMS documentation to be translated and filed as part of the NMPA dossier, with specific formatting expectations. A single QMS must be structured to accommodate all of these overlay requirements simultaneously.
Local Representatives: Four Different Structures, Four Different Risks
The local representative obligation is present in all four markets but is structured very differently. The EU Authorised Representative under Article 13 of the MDR is the most operationally significant: the EU AR's name must appear on device labelling, their EUDAMED SRN must be registered and displayed, and they bear legal liability for the device in the EU market. A manufacturer who terminates their EU AR relationship mid-certificate cycle faces an immediate market access problem — the device cannot be placed on the EU market without a registered EU AR, and EUDAMED registration must be updated before the device can continue to be distributed.
The China agent creates a different but comparably significant risk. Because the China agent's name appears on the NMPA registration certificate itself — not just on the labelling — any change to the China agent requires a formal certificate amendment through the CMDE. This is a process that takes significant time and cannot be done reactively in response to a commercial dispute or service failure. Manufacturers entering the Chinese market must treat the China agent appointment as a long-term structural commitment, not a vendor relationship that can be changed with a notice period.
Selling medical devices across multiple markets?
TGC supports manufacturers with EU MDR/IVDR conformity preparation, EUDAMED registration, QMSR gap assessments, UK Responsible Person appointments, and NMPA registration management — coordinated across all four markets.